Competitive Outlook on Non-Antibody Based Cancer Vaccines - Biologics Market Research

Competitive Outlook on Non-Antibody Based Cancer Vaccines
BioSeeker Group AB
August 3, 2006
Pub ID: BIOS1325347
US $2,574.00 Hard Copy Mail Delivery
US $2,574.00 PDF E-mail From Publisher
Abstract
Introduction
New approaches in vaccines, such as DNA vaccines, new combination vaccines, new formulations, novel delivery routes, new adjuvants are being explored. In the last three years the cancer vaccine industry has reshaped itself quite considerably. The number of cancer vaccine players has rather decreased than increased, through operational re-prioritizations, M&As and fall outs.
Scope of this report
In-depth competitive landscape assessment of the cancer vaccine market
Tumor antigen discovery and technologies surrounding it
Thorough review of immunomodulating strategies and adjuvants
Thorough review of cancer vaccine delivery and technologies surrounding it
Progress analysis of six major cancer vaccine indications, including players, drugs, clinical progress and pitfalls
Research and analysis highlights
Research and development in the cancer vaccine field is dominated by its top 10 players, interestingly not including any of the big pharma companies per se. The recent Gardasil approval and GlaxoSmithKline?s acquisition of Corixa will certainly push the industry towards more acquisitions. With this in mind, this report makes an in-depth assessment of competitive landscape, tumor antigen technologies, immunostimulatory strategies, vaccine delivery technologies, and a progress analysis of six major cancer vaccine indications.
Key reasons to read this report
Understand the clinical and strategic challenges to the commercialization of cancer vaccines
Assess opportunities and risks for the continued development of cancer vaccines in six major cancer indications.
Adopt knowledge from this analysis to drive strategic planning decisions in oncology drug development"